Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synbio TechROCO:1295 -0.40%44 EBITDA Margin % is 25.91% as of Dec. 2025, which is 13% below its 10-year median of 29.82. GuruFocus rates ROCO:1295 with a GF Score™ of 44/100. The stock has 10 warning signs investors should review. Among 939 Biotechnology companies, Synbio Tech ranks better than 87.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Synbio Tech's EBITDA for the
three
months ended in Dec. 2025 was NT$74 Mil. Synbio Tech's Revenue for the
three
months ended in Dec. 2025 was NT$285 Mil. Therefore, Synbio Tech's EBITDA margin for the quarter that ended in Dec. 2025 was 25.91%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Synbio Tech EBITDA Margin % Related Terms
Synbio Tech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Synbio Tech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1295 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Synbio Tech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synbio Tech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synbio Tech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Synbio Tech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synbio Tech (ROCO:1295) has a EBITDA Margin % of 25.91% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synbio Tech and its competitors. This is 13% below median its historical median of 29.82. Over the past decade, Synbio Tech's EBITDA Margin % has ranged from 27.14 to 32.14. According to the industry distribution chart, Synbio Tech ranks #115 out of 939 companies in the Biotechnology industry, placing it in the top 12.2%.
Is Synbio Tech's EBITDA Margin % too high?
Synbio Tech's current EBITDA Margin % of 25.91% is 13% below median its 10-year median of 29.82. Over the past 10 years, this metric has ranged from a low of 27.14 to a high of 32.14. Based on the distribution chart, Synbio Tech ranks #115 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Synbio Tech has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Synbio Tech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Synbio Tech ranks #115 out of 939 companies for EBITDA Margin %. This places Synbio Tech in the top 12% of its industry — outperforming the majority of peers. Historically, Synbio Tech's own EBITDA Margin % has ranged from 27.14 to 32.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Synbio Tech and its competitors. Synbio Tech's current EBITDA Margin % is 25.91%, which is 13% below median its own 10-year median of 29.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synbio Tech stock overvalued right now?
Synbio Tech (ROCO:1295) has a current EBITDA Margin % of 25.91%. The current EBITDA Margin % is 25.91%, which is 13% below median its 10-year median of 29.82. Synbio Tech's overall GF Score™ is 44/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Synbio Tech (ROCO:1295), the current EBITDA Margin % is 25.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Synbio Tech Inc focus on functional research and manufacturing of probiotics for human health and economic animals. It has two reportable segments, Taiwan and Mainland China Segment to engage in the production and R&D technologies of the Taiwan Segment, including the production and sales of concentrated fermentation liquid, lactobacillus plantarum solid drinks, and lactobacillus plantarum granules for animal husbandry. It generates majority of revenue from Taiwan segment includes production and sale of lactobacillus plantarum powder, lactobacillus plantarum fermentation derivative products, probiotics dietary supplements, probiotics products for pets and economic animals, and probiotics products. It has presence in Taiwan, China, Southeast Asia, and Others.
44GF Score
Get the complete analysis for ROCO:1295
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1295 has been successfully added to your 
